Cardiac Safety Screening with ValaDATE.AI™ & proph𝔼CG™

ValaDATE.AI™ with proph𝔼CG™ is the most clinically predictive cardiotoxicity solution, setting the gold standard for fast, accurate, and cost-effective drug screening.

Access the Leading Human Cardiac Toxicity Assessment

Experience the most advanced and clinically predictive in vitro human cardiotoxicity assay available. ValaDATE.AI™ with proph𝔼CG™ revolutionizes drug safety screening with unmatched accuracy and predictive cardiac safety insights to ensure optimal patient outcomes and minimize drug trial risks.

Key Benefits of ValaDATE.AI™ with proph𝔼CG™ for Drug Safety Screening

Superior Performance – Surpasses hERG assays, CiPA, and other cardiotoxicity tests.
High Accuracy – 97% clinical predictivity for key cardiac metrics like QT prolongation, arrhythmia, and cardiac arrest.
Early Detection – Identifies drug-induced ECG and echocardiogram changes before patient exposure.
Faster & Cost-Effective – Speeds up screening while cutting costs.
Ethical & Reliable – Uses human-relevant in vitro data, eliminating unreliable animal models.

See Example Data

How ValaDATE.AI™ with proph𝔼CG™ Transforms Cardiac Safety Testing

Powered by Vala’s patented video processing technology, ValaDATE.AI™ with proph𝔼CG™ (predictive optical physiology of human 𝔼CG) converts in vitro cellular waveform data into actionable cardiac safety reports that predict drug-induced changes in human echo- and electrocardiograms with up to 97% accuracy.

Here's how it works:

Step 1

Replace unreliable animal studies with clinically-relevant human heart cells.

Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes from healthy or diseased patients are used to create clinical-trials-in-a-dish.

Step 2

Video capture of human heart cellular activity.

Implement KIC® high-content optical electrophysiology for 4-in-1 multiplex imaging of voltage, calcium, contraction and mitochondrial health.

Step 3

Image segmentation and single-cell identification.

CyteSeer® computer vision AI identifies every cell in every video frame, facilitating high resolution single-cell analysis.

Step 4

Single-cell waveform and transient data extraction.

CyteSeer® automatically extracts the cellular activity waveforms and transients from every cell.

Step 5

Comprehensive measurements for every transient.

CyteSeer® interpretable AI algorithms analyze each transient, assessing hundreds of parameters per readout to yield 20 million metrics per drug tested.

Step 6

Predict echo- and electrocardiogram class effects.

proph𝔼CG™ translates key parameters into highly clinically relevant echo- and electrocardiogram (ECG) class predictions.

proph𝔼CG™ class predictions:

Heart Rate - Beats per minute, number of transients
QT Interval - ECG interval from the Q wave to after the T wave, related to transient duration, QT prolongation
QRS Interval - ECG interval related to transient upstroke alterations
TU Interval - ECG interval including T and U waves (associated with arrhythmias), corresponding to triangulation, early afterdepolarization (EAD) and delayed afterdepolarization (DAD)
Arrhythmia - ECG class associated with most overt arrhythmias (e.g., extended alternans)
Arrest - ECG class related to a transient peak to baseline ratio <10% versus control, percent of cells with zero transients

Step 7

Report the margin of safety for each drug tested.

proph𝔼CG™ calculates the margin of safety by dividing the effective drug concentration by the free effective therapeutic plasma concentration (or the minimum test concentration in blinded studies), providing a measure of drug safety related to the therapeutic index where a larger number is safer.

ValaDATE.AI™ with proph𝔼CG™ Transforms Drug Discovery by Redefining Safety

Drug-induced cardiotoxicity is a major cause of treatment failure and patient harm. Vala Discovery's state-of-the-art drug screening technology is shaping the future of safer, more effective treatments.

Join us in redefining safety for patients with ValaDate.AI™ and proph𝔼CG™.